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Abstract
Introduction: Early antiretroviral therapy (ART) has improved neurodevelopmental outcomes of HIV-infected (HIV-positive)
children; however, little is known about the longer term outcomes in infants commencing early ART or whether temporary ART
interruption might have long-term consequences. In the children with HIV early antiretroviral treatment (CHER) trial, HIV-
infected infants ≤12 weeks of age with CD4 ≥25% were randomized to deferred ART (ART-Def); immediate time-limited ART
for 40 weeks (ART-40W) or 96 weeks (ART-96W). ART was restarted in the time-limited arms for immunologic/clinical progres-
sion. Our objective was to compare the neurodevelopmental profiles in all three arms of Cape Town CHER participants.
Methods: A prospective, longitudinal observational study was used. The Griffiths mental development scales (GMDS), which
includes six subscales and a global score, were performed at 11, 20, 30, 42 and 60 months, and the Beery-Buktenica develop-
mental tests for visual motor integration at 60 months. HIV-exposed uninfected (HEU) and HIV-unexposed (HU) children were
enrolled for comparison. Mixed model repeated measures were used to compare groups over time, using quotients derived
from standardized British norms.
Results: In this study, 28 ART-Def, 35 ART-40W, 33 ART-96W CHER children, and 34 HEU and 39 HU controls were
enrolled. GMDS scores over five years were similar between the five groups in all subscales except locomotor and general
Griffiths (interaction p < 0.001 and p = 0.02 respectively), driven by early lower scores in the ART-Def arm. At 60 months,
scores for all groups were similar in each GMDS scale. However, Beery visual perception scores were significantly lower in
HIV-infected children (mean standard scores: 75.8 ART-Def, 79.8 ART-40W, 75.9 ART-96W) versus 84.4 in HEU and 90.5 in
HU (p < 0.01)).
Conclusions: Early locomotor delay in the ART-Def arm resolved by five years. Neurodevelopmental outcomes at five years in
HIV-infected children on early time-limited ART were similar to uninfected controls, apart from visual perception where HIV-
infected children scored lower. Poorer visual perception performance warrants further investigation.
Keywords: HIV care continuum; Children; ARV; CHER trial; Early time-limited antiretroviral therapy; Neurodevelopment;
Treatment interruption; Griffiths mental development scales; Visual perception
Additional Supporting Information may be found online in the Supporting information tab for this article.
Received 21 August 2017; Accepted 8 March 2018
Copyright © 2018 The Authors. Journal of the International AIDS Society published by John Wiley & sons Ltd on behalf of the International AIDS Society. This is an
open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
1 | INTRODUCTION
HIV encephalopathy, a common finding in perinatally HIV-
infected children, has decreased since the introduction of
combination antiretroviral therapy (ART) [1]. Other neurode-
velopmental deficits despite ART remain a concern. Although
early viral suppression is beneficial for neurodevelopmental
outcomes [2-5], the long-term outcomes of children after early
ART are unclear and may be compromised by cumulative toxi-
city or waning adherence. Early treatment with planned inter-
ruptions after early virological suppression is a possible
solution.
The Children with HIV Early Antiretroviral (CHER) trial
conducted in South Africa (2005 to 2011) compared early
time-limited ART with deferred ART in asymptomatic HIV-
infected infants [6,7]. HIV-infected infants with CD4 ≥25%
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were randomized to one of three strategies: (i) ART deferred
until indicated (ART-Def), (ii) early limited ART for 40 weeks
(ART-40W) and (iii) early limited ART for 96 weeks
(ART-96W). Continuous ART was initiated (in ART-Def) and
re-initiated (in ART-40W and ART-96W) if CD4% declined
<25% in the first year of life and <20% thereafter, or for pro-
tocol-defined severe stage B or stage C clinical disease. After
a median of 4.8 years, the superiority of early time-limited
over deferred continuous ART was confirmed [6].
A neurodevelopmental sub-study of CHER found signifi-
cantly better locomotor and general development scores at
11 months for early ART, with children in ART-Def scoring
significantly lower than the combined early ART arms. How-
ever, the early treatment arms had not yet interrupted ART
[8]. These neurodevelopmental outcomes contrast with older
children from the PREDICT study which showed no difference
between early versus deferred ART in children with CD4 15%
to 24%. In PREDICT, HIV-infected children performed worse
than uninfected controls [9].
Here, we present the neurodevelopmental profiles over five
years of this CHER sub-study which includes data from the
treatment interruption phase. We hypothesized: firstly that
the early treatment arms would do better than the deferred
arm, and that the improved neurodevelopmental outcomes
seen at 11 months in the early treatment arms would persist
despite time off therapy, and be similar to HIV-uninfected con-
trols; secondly that within the early treatment groups, care-
fully guided ART interruption would not affect
neurodevelopmental outcomes.
2 | METHODS
2.1 | Study Design and Participants:
This was a prospective, longitudinal observational sub-study of
CHER trial, conducted at the Cape Town site only, between
2006 and 2013. Of 411 infants enrolled onto CHER with CD4
≥25%, 119 HIV-infected infants in Cape Town were available,
along with 42 perinatally HIV-exposed uninfected (HEU) and 42
HIV-unexposed (HU) controls from a concurrent linked vaccine
study [10]. Inclusion criteria for the sub-study were: birthweight
>2000 g, normal neurological examination at a clinical visit near
three months of age, no dysmorphic syndromes or central ner-
vous system (CNS) insults, for example foetal alcohol exposure,
birth asphyxia or metabolic abnormalities. HEU and HU controls
were enrolled at the same time to provide a reference group
for interpreting neurodevelopmental scores within the socio-
economic and cultural context. HEU infants also controlled for
ART exposure to prevent mother to child transmission (PMTCT)
and circumstances surrounding growing up with an HIV-
infected mother. Mothers or legal guardians were approached
from 2006 during a CHER or Vaccine study visit. Written con-
sent was obtained in their preferred language. Participants who
missed early enrolment were included at a later visit. The Stel-
lenbosch University Health Research Ethics Committee
approved the study, registration: N05/05/092. Due to attrition
of controls, additional five year old Xhosa children (7 HEU, 3
HU) were enrolled from the original source communities in
2012. Eligibility criteria included documented evidence of
mother’s HIV-negative status at birth, child’s HIV-1 antibody
test negative, birthweight >2000 g, no history of CNS insults,
being clinically healthy with normal medical history and general
examination performed by a study doctor.
2.2 | Neurodevelopmental Assessments:
The Griffiths Mental Development Scales (GMDS) were per-
formed at a CHER study visit. The baby scales (0 to 2 years)
were used at 11 and 20 months [11] and the extended revised
version (2 to 8 years) at 30, 42 and 60 months [12]. The GMDS
assesses neurodevelopment on six subscales: locomotor, per-
sonal-social, hearing and language, eye and hand coordination,
and performance (visuospatial skills including speed and preci-
sion), adding practical reasoning after 24 months. A general
Griffiths score, an average of the subscales, is also obtained.
One of the four GMDS-trained paediatricians conducted the
assessments, assisted by a GMDS-trained translator using stan-
dardized translations, all blinded to treatment arm allocation.
One paediatrician conducted only four assessments, all at
11 months. The other three assessed at all time points. At the
beginning of each age time point, the paediatricians assessed a
child together and marked independently, and compared scores
and discussed discrepancies afterwards. This was repeated on
different children until scoring was similar. The GMDS provides
standardized norms from typical British children. Quotients
were used to compare performance at different time points. The
0 to 2 year scale provides quotients from raw scores, and 2 to
8 year scales provide percentiles and z-scores. For 2 to 5 year
olds, we converted raw scores into age equivalents (from the
standardized scores 50th percentiles) and calculated a quotient
as a percentage of the child’s chronological age, for the sub-
scales and general Griffiths. At 60 months of age, the Beery-
Buktenica developmental tests of visual motor integration
(Beery-VMI), visual perception and motor coordination (sixth
edition) were administered [13]. The Beery-VMI measures the
ability to coordinate visual perceptual and motor skills by copy-
ing geometric forms. Visual perception requires the child to iden-
tify matching forms, and motor coordination involves drawing
the forms by connecting dots and staying within paths provided,
abilities that are not assessed in the GMDS. Standard scores
were calculated from raw scores using USA norms. Neurodevel-
opmental scores are standardized with a mean (SD) quotient or
standard score of 100 (15), scores of 90 to 109 are considered
average and <70 as intellectual impaired/delayed [11,13].
Neurological examination and head circumference measure-
ment were performed at each visit and the Child Behavior
Checklist completed at 20, 42 and 60 months (reported else-
where) [14]. Parents or caregivers received a written report
after each assessment with advice for stimulating weaker areas
of development. Children with suspected sensory deficits or sig-
nificant developmental delay were referred to appropriate diag-
nostic and therapeutic services. We included assessments
previously reported at 11 months [8] to better present the lon-
gitudinal developmental profile over five years. Primary end-
points were neurodevelopmental scores at each assessment.
2.3 | Clinical data
On CHER, HIV-infected participants had regular clinical visits:
every 4 weeks until week 24, every 8 weeks until week 48
and then every 12 weeks. Assessments included: physical
examination, ART adherence and management of any illnesses
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or adverse events, and T-cell subsets were done. HIV-RNA
viral loads (VL) were only performed if treatment failure was
suspected until November 2009, thereafter VL were per-
formed 6 monthly. A blinded independent clinical endpoint
review committee adjudicated CDC severe stage B and C
events and HIV encephalopathy diagnosis without knowledge
of CD4 values, ART status or treatment group [6,7]. HEU and
HU children had three monthly clinical assessments for
18 months and then annually thereafter [10].
Demographic and clinical information were obtained from the
CHER database. In HIV-infected participants, viral load (VL) and
CD4 values from baseline and within six months of the
60 months assessment were used, together with baseline CMV
viraemia [15]. HIV-negative status of controls on the vaccine
trial was confirmed between 16 and 28 weeks of age [10].
2.4 | Statistical analysis
We used Statistica version 13 (software.dell.com. Dell Inc.
2015). The primary analysis compared neurodevelopmental
quotients over time in five groups (three HIV-infected: ART-
Def, ART-40W and ART-96W, and two uninfected: HEU, HU)
using linear mixed models with group and time as categorical
fixed effects, and participants as random effect. We opted for
parsimony and therefore compound symmetry was used. Sam-
ple size calculations were based on predicted neurodevelop-
mental outcomes, which we expected to be larger. To detect
an average effect size of 7.5 (half SD on GMDS and Beery
tests) at 5% significance level, 30 per group would provide
90% power and 25 per group 80% power.
Due to concerns about using British norms for GMDS out-
comes, we conducted post-hoc analyses using age-adjusted
raw scores. Comparison of scores over 5 years was not possi-
ble, due to differences in raw score calculation <2 years and
>2 years. We therefore compared, time points 1 to 2 and time
points 3, 4 and 5 separately.
Summary statistics for background information were com-
pared using chi-squared test for categorical variables and one-
way analysis of variance (ANOVA) for continuous measures.
Mean (SD) or median [IQR] were reported, depending on nor-
mality and homogeneity of variance.
Additional analysis was performed combining the three
HIV-infected arms. Spearman correlations were determined
between neurodevelopmental outcomes at 60 months and the
following: (i) age at starting ART, (ii) time on ART, (iii) time to
VL suppression (age at first VL <400 copies/ml) and (iv) CD4
values at enrolment onto CHER. A 95% confidence interval
was calculated and significance established at p < 0.05. For
variables in the mixed model analysis, the Fisher least signifi-
cant difference was used.
3 | RESULTS
3.1 | Participants
Ninety-six HIV-infected infants of the 119 CHER trial partici-
pants in Cape Town were enrolled in the neurodevelopmental
sub-study: 28 ART-Def (excluded two refusals and eight
deaths before 11 months), 35 ART-40W (excluded four refu-
sals and two to foetal alcohol exposure (FAE)) and 33 ART-
96W (excluded four refusals and one glutaric-aciduria, one
FAE, one non-adherence to CHER protocol); 63 of 84 unin-
fected controls from the vaccine study were enrolled; and 10
additional controls at 60 months (total enrolled: 34 HEU, 39
HU). One infant in ART-96W died at 21 months (disseminated
tuberculosis) and one HU child died at 48.5 months (motor
vehicle accident). At 60 months, retention in arms was 26/28
(93%) in ART-Def, 29/35(83%) ART-40W and 23/33(70%)
ART-96W, and retention in controls from baseline was 15/27
(56%) in HEU and 25/36(69%) HU. For details on participants
enrolled and assessed at each time point, see Figure S1.
3.2 | Participant Characteristics
There were more boys in the controls than the HIV-infected
groups (Table 1). Birthweight was similar between groups. There
was variability in the mode of delivery, with vaginal deliveries
ranging from 68% (HEU) to 86% (ART-40W). For PMTCT, most
mothers and babies received nevirapine and zidovudine. Three
HIV-positive mother-child dyads had no PMTCT. The mean age of
mothers at birth of HEU infants was slightly older than the other
groups (30.9 years vs. means between 27 and 28 years).
Maternal education level was similar between groups. Almost all
HIV-infected infants, but only 36% of HU infants, were Xhosa-
speaking. In the HIV-infected groups, baseline CD4 parameters
and mean VL were similar while the proportion with CMV
viraemia at baseline ranged from 13% to 29%.
Of HIV-infected participants enrolled, those developing
CDC stage severe B or stage C diagnosis were 10/28(36%) in
ART-Def, 15/35(43%) in ART 40W and 11/33(33%) in ART
96W. These included HIV encephalopathy in four (14%) ART-
Def (diagnosed at 5, 9, 31 and 61 months), five (14%) ART-
40W infants (at 19, 20, 21, 24 and 31 months) and two (6%)
ART-96W (at 10 and 31 months). Table 2 further describes
characteristics of HIV-infected participants.
3.3 | Neurodevelopmental assessments and
outcomes:
In general, mean GMDS scores declined over time in all sub-
scales and in all groups, including controls. The most signifi-
cant differences in longitudinal profile between groups were
in the locomotor subscale (p < 0.001) and general Griffiths
scale (p = 0.02), driven by initial lower scores in ART-Def
arm at 11 and 20 months. The control groups had higher
scores than the HIV-infected arms at the first three assess-
ments in most subscales. However, scores for all groups were
similar at 42 and 60 months, with mean quotient for each
group ranging from 93.2 to 98.7 for the locomotor subscale
and from 81.8 to 84.7 for general Griffiths (Figure 1 and
Table 3). Not all children were assessed at each time point
due to missed visits or withdrawal, mainly relocation to rural
areas.
Results for raw scores (controlling for age) were similar to
those for quotients. Differences in developmental profile
between groups in the locomotor subscale were confirmed
between 30, 42 and 60 months (interactive p = 0.009), but
the general Griffiths was not as robust (interactive = p 0.1).
The raw scores also confirmed significant differences in pair-
wise comparisons between groups in early assessments, and
no difference between arms at 5 years, observed for compar-
ing the quotients. Analysis of raw scores in other Subscales
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confirmed no difference in profiles. (See Supplementary
material Tables S3, S4 and S5).
For visual perception at 60 months, the HIV-infected
groups scored 5 to 9 points lower than HEU group and 10 to
14 points lower than HU, but Beery-VMI and motor coordina-
tion were similar (Table 4). During assessments, no children
were suspected of having visual problems.
3.4 | Antiretroviral therapy and responses:
Children on early ART began first-line therapy (zidovudine, lami-
vudine and lopinavir/ritonavir) at a meanSD of 1.3  0.5
months (ART-40W) and 1.5  0.5 months (ART-96W) com-
pared to ART-Def (6.8  3.5 months; range 3.9 to 17.7)
(Table 2). For ART-40W, of 35 enrolled, two left the study
before 40 weeks and 4 met criteria for not interrupting; 29/33
(88%) interrupted at a mean age of 11.4 months for a median of
7.0 [IQR 5.0 to 11.0] months. At 60 months, one was still off
ART. For ART-96W, of 33 enrolled, three left the study, one died
before 96 weeks and nine met criteria for not interrupting; 20/
29(69%) interrupted treatment at a mean age of 24.5 months
for a median of 8.0 [IQR 7.0 to 36.0] months (one withdrew
before restarting). At 60 months, 14 had restarted and five
were still off ART. The meanSD cumulative time on ART until
60 months was similar among ART-40W and ART-96W and
shorter than ART-Def. One child changed to second line ART at
2 years due to CD4 <20% (in ART-40W). Table 2 describes the
proportion of participants off ART of those assessed at each
assessment.
3.5 | Clinical measures at five years
The proportion of infants with severe CDC stage B or C and
HIV encephalopathy of those assessed at 5 years is described
in Table 2. At 60 months, 92% in ART-Def, 97% in ART-40W
and 74% in ART-96W had VL <400 copies/ml. Mean CD4
parameters and mean WHO height-for-age z-scores were sim-
ilar in the groups.
3.6 | Correlations between clinical parameters and
neurodevelopment at five years
Combining all HIV-infected infants, correlations were weak
between neurodevelopmental outcomes at five years and age
starting ART, baseline CD4 count, time on ART and time to
first VL suppression (Spearman r between 0.19 and 0.08).
Table 1. Demographic data and clinical characteristics of all study participants
HIV infected Uninfected
p valueART-Def (n = 28) ART-40W (n = 35) ART-96W (n = 33) HEU (n = 34) HU (n = 39)
Gender: Male 11 (39%) 15 (43%) 13 (40%) 19 (56%) 23 (59%) 0.29*
Birthweight, g, mean (SD) 3036 (407) 3096 (445) 2912 (411) 3090 (513) 3127 (561) 0.36*
Delivery
NVD n (%) 20 (71%) 30 (86%) 28 (85%) 23 (68%) 31 (84%)
C/S n (%) 8 (29%) 5 (14%) 5 (15%) 11 (32%) 6 (16%) 0.23*
Unknown 2
PMTCT exposure
Mother n (%) 27 (96%) 31 (89%) 31 (84%) 29 (85%) – 0.14#
Child n (%) 25 (89%) 32 (91%) 32 (97%) 29 (85%) – 0.15#
No PMTCT n 0 2 1 0
Unknown n 0 0 0 5 (15%)
Mother’s age at birth (years) mean (SD) 27.2 (5.1) 27 (4.4) 27.2 (5.8) 30.9 (14.1) 28 (7.2) 0.26*
Mother’s education mean (SD)
(highest grade attended)
10.0 (2.1) 9.4 (2.3) 9.4 (2.7) 9.9 (2.4) 9.8 (2.0) 0.70*
Language
Xhosa n (%) 27 (96%) 32 (91%) 30 (91%) 28 (88%) 14 (36%) <0.001*
Afrikaans n 1 3 3 4 25
English n 2
Mean (SD) at baseline
CD4 count (cells/ll) 1781 (672) 2082 (968) 2076 (1151) – – 0.39§
CD4% 35.8 (8.4) 35.5 (8.6) 34.5 (8.6) 0.81§
Viral load at baseline copies/ml
Mean (SD)
598,504 (243,254) 528,435 (250,021) 593,933 (244,958) – – 0.38§
CMV PCR at baseline n (%)
>25 copies/ml
5/25 (20%) 8/28 (29%) 4/30 (13%) – – 0.35§
Treatment groups: ART-Def: ART deferred until symptomatic, ART-40W: early ART until 40 weeks then planned interruption, ART-96W: early
ART until 96 weeks then planned interruption. Control groups: HEU: HIV-exposed uninfected, HU: HIV-unexposed. Chi-square for categorical vari-
ables and ANOVAs for continuous variables
p values: *between 5 groups, #between 4 groups, §between 3 groups.
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Higher baseline CD4% correlated significantly with lower
locomotor motor scores (r 0.23; p = 0.03) and marginally
with Beery-VMI (r 0.2; p = 0.06) and motor coordination
(r 0.1; p = 0.06). (Supplementary Material Tables S1 and
S2).
4 | DISCUSSION
Through serial testing, we demonstrated poorer locomotor
and general Griffiths scores in ART-Def at 11 and 20 months
of age, which had resolved by 42 months and was maintained
at five years. The limited differences between groups over
time on personal-social, language, eye and hand coordination,
performance and practical reasoning GMDS subscales is
encouraging. Our findings suggest that limited ART interrup-
tion under careful clinical guidance in asymptomatic children
starting ART ≤12 weeks of age did not negatively affect their
neurodevelopmental outcomes at five years. This supports
clinical, immunological and virological findings from the larger
CHER cohort that early time-limited ART appears safe [6].
At 11 months, neurodevelopmental scores of ART-Def were
generally lower than the other arms. Our longer term findings pro-
vide new evidence that catch-up/recovery is possible after delayed
ART initiation. However, eight early deaths in ART-Def prior to
GMDS assessments may have contributed to a survivor effect.
Our finding that all HIV-infected arms had visual perceptual
scores significantly below HU children at 5 years, is concern-
ing. Similarly, two HIV-infected arms (ART-Def and ART-40W)
also scored significantly below HEU children. This was despite
viral suppression and suggests that HIV adversely affects
visual perception regardless of ART strategy. However, cultural
differences in early childhood stimulation may have influenced
these findings as there were more Afrikaans-speaking children
Table 2. Descriptive characteristics of HIV-infected participants
Antiretroviral therapy for all enrolled participants
ART-Def ART-40W ART-96W
p valueN = 28 N = 35 N = 33
Age at ART initiation, months mean (SD) 6.8 (3.5) 1.3 (0.5) 1.5 (0.5) <0.001
Treatment interruption: n (%) Not applicable 29/35 (88%) 20/33 (61%) 0.04
Median [IQR] time interrupted (months) 7 [5 to 11]a 8 [7 to 36]b
Assessments at each time in time-limited treatment groups and proportion off ART
ART 40-W ART-96W
Assessment age Number assessed Number interrupted (%) Number assessed Number interrupted (%)
11 months 34 0 32 0
20 months 33 14 (42%) 29 0
30 months 32 5 (16%) 28 16 (57%)
42 months 29 1 (4%) 26 6 (23%)
60 months 29 1 (4%) 23 5 (22%)
Antiretroviral therapy and clinical parameters at five years for those assessed at 5 years
ART-Def ART-40W ART-96W p value
N = 26 N = 29 N = 23
Cumulative time on ART at 5 years.
assessment, (months) mean (SD)
54.6 (3.6) 49.4 (12) 48.1 (14.5) <0.001
Severe stage B/C diagnosis, n (%) 9 (35%) 13 (45%) 6 (26%) >0.2c
HIV encephalopathy, n (%) 4 (15%) 4 (14%) 2 (9%) >0.5 c
CD4 count mean (SD) 1080 (363) 1192 (492) 1032 (541) 0.45
CD4% mean (SD) 36.6 (5.8) 34.4 (6.9) 33.1 (8.2) 0.22
VL <400 copies/ml 24/26 (92%) 28/29 (97%)a 17/23 (74%)b
WHO height-for-age z-score mean (SD) 0.64 (1.0) 0.90 (1.2) 0.83 (0.8) 0.59
WHO weight-for-age z-score mean (SD) 0.09 (1.1) 0.05 (1.1) 0.26 (0.8) 0.44
Treatment groups: ART-Def: ART deferred until symptomatic, ART-40W: early ART until 40 weeks then planned interruption, ART-96W: early
ART until 96 weeks then planned interruption.
aIncludes 1 who had not yet restarted ART at 60 months.
bIncludes 5 who had not yet restarted ART at 60 months and one left study before restarting.
cPairwise chi-square comparison between groups.
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Figure 1. Comparison of Griffiths scales of mental development scores over time per arm. LS means, Type III decomposition, Vertical bars denote
0.95 confidence intervals, interaction p-values. X Axis: Mean age at time points: 1 = 11 months, 2 = 20 months, 3 = 30 months, 4 = 42 months,
5 = 60 months. Note: Lines connecting scores added for visual clarity and do not imply participants identical at each time point.
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in the HU group. This observation requires further investiga-
tion as visual perception may be the underlying cause of defi-
cits found in later childhood. Visual perception involves
recognition and discrimination of visual shapes and objects.
This process involves the cognitive components and executive
tasks of visual attention, memory, discrimination and imagery.
Perceptual identification is processed by the ventral stream
pathway [16], which may be vulnerable to HIV. Deficits may
impair reading, writing and mathematics achievement [17].
Deficits in visual spatial organization, processing and working
memory have been described in HIV-infected children, even in
the context of normal cognitive development, higher CD4
counts or clinical stability [18-21]. Interestingly, there was no
difference between groups on the Beery-VMI and motor coor-
dination tests. Abnormal visual perception in children with
normal Beery-VMI scores has been described [17]. It is impor-
tant to consider that the Beery-VMI may not be sensitive
enough to measure the specific visual perceptual deficit
caused by HIV in young children.
It is possible that ART interruption at 96 weeks may be bet-
ter than at 40 weeks, as suggested in the main results paper
[6]. There was more HIV encephalopathy in ART-Def and ART-
40W compared to ART-96W, and ART-40W also had more
CDC severe stage B and stage C diagnoses than the other
arms, with the increase occurring largely between the 11 and
18 months’ assessments during treatment interruption. On the
other hand, fewer children underwent interruption or had base-
line CMV viraemia in ART-96W. Interpreting the effects of
treatment interruption is difficult as some children randomized
to ART-40W or ART-96W were not interrupted, there was a
wide range of time off ART, and ART-Def had a longer mean
time on ART than the early time-limited arms.
On secondary analysis there were no significant correlations
between neurodevelopmental outcome at five years and the
following parameters: age at starting ART, time to first viral
suppression and time on ART. Interestingly, a higher CD4% at
baseline significantly correlated with lower locomotor scores
(Spearman r of 0.23) and marginally correlated with lower
Beery-VMI and motor coordination scores. Although counter-
intuitive, we considered a number of explanations. A higher
CD4% in ART-Def may have led to a longer period of obser-
vation prior to ART initiation; those on time-limited ART
(ART-40W and ART-96W) may have been more likely to inter-
rupt ART than in those who reached an endpoint prior to
interruption so would have remained on continuous ART. This
issue requires further exploration.
It is interesting to note that on the locomotor subscale, the
mean quotients decreased over time in both uninfected
groups while increasing in HIV-infected arms. Similar decline
over time was noted in most other subscales. The ART-Def
and ART-40W arms may be demonstrating catch up due to
longer time on suppressive ART from an early age. However,
this should be interpreted with caution due to small numbers
in infected arms and the enrolment of additional controls at
five years.
The GMDS may be insufficiently sensitive to discriminate
between the groups at five years, thus creating an impression
of “catch up” in the infected groups. Alternatively, the effects
of poverty and deprivation on early childhood development
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The decline in all GMDS scores except for the personal-
social subscale most likely reflects the application of British
norms [11,12] to South African children from impoverished
environments, and emphasizes the importance of having unin-
fected controls from the same communities. The GMDS has
Xhosa and Afrikaans translations, is widely used in South
Africa and thought to be culturally fair [24-26]. However, cau-
tion should be used when interpreting these results for clinical
purposes. In a post-hoc analysis, the longitudinal profiles of
age-adjusted raw scores supports our findings when using
quotients for locomotor; however, there is a weaker associa-
tion with general Griffiths and similar scores between groups
at five years. We did not see a decline in scores over time for
raw scores. (See supplemental material Tables S4 and S5)
The strengths of the study are that this is a relatively cohe-
sive sample recruited from communities with minimal prenatal
substance abuse and includes uninfected children from the
same communities.. The similar demographic and clinical char-
acteristics in the HIV-infected arms reflect successful random-
ization of this sub-study within the main trial. A further
strength is the longitudinal nature of assessments, despite rel-
atively small numbers and some attrition.
4.1 | Limitations
Our results should be considered within the context of small
numbers and variability between groups. The original sample
size for this study was calculated assuming a larger difference
in neurodevelopmental scores between groups and larger
group numbers. Some missed visits and attrition further
reduced sample sizes. An inherent bias was that controls had
less clinical contact time than HIV-infected children as they
had no medication visits, and additional controls were added
at five years. Although there were more Afrikaans-speaking
HU participants, they were from similar socio-economic back-
grounds to the Xhosa-speaking participants with similar neu-
rodevelopmental trajectories. However, we cannot rule out
the cultural effects of early childhood rearing practices which
may have influenced some comparisons. While we acknowl-
edge that illnesses and maternal depression are important
influences on early childhood development, we exclude the
effects of hospitalizations and maternal depression due to
small sample sizes relative to the number of arms and assess-
ment time points. We have previously described the high inci-
dence of maternal depression and effects of maternal trauma
in this cohort [14,27]. As we did not determine whether the
HIV infection occurred in utero or perinatally, each arm had
potential heterogeneity, making further interpretation of ART
interruption difficult.
Nevertheless, we found that early ART improved neurode-
velopmental outcomes. Planned treatment interruption
appeared safe in children who suppressed early. This is reas-
suring for situations where ART interruption is unavoidable,
for example lack of supplies or social/political disruption.
All HIV-infected children should be assessed for visual per-
ceptual deficits and referred for intervention as needed, to
improve educational outcomes.
5 | CONCLUSIONS
HIV-infected children on ART-Def arm had locomotor delay at
younger ages, which recovered by 5 years. For children with
perinatal HIV infection, the neurodevelopmental outcomes at
five years of asymptomatic children with preserved CD4 T-cell
percentages and receiving early but limited ART under strict











n = 28 p value
Visual motor integration (VMI)
Mean quotient SD 89.7  9.0 89.0  7.3 90.3  11.7 88.0  10.3 92.7  10.5 0.89
95% CI (86.1 to 93.3) (86.2 to 91.8) (85.2 to 95.4) (83.3 to 92.7) (88.6 to 96.7)
Visual perception
Mean quotient SD 75.8  15.9a 79.8  14.7a 75.9  13.5 84.4  13.5b 90.5  9.3 <0.01
95% CI (69.2 to 82.3) (74.1 to 85.5) (69.9 to 81.9) (77.9 to 90.9) (86.9 to 94.1)
Motor coordination
Mean quotient SD 94.110.6 93.68.4 96.57.3 93.912.3 92.912.3 0.8
95% CI (89.8 to 98.3) (90.4 to 96.8) (93.3 to 99.7) (88.3 to 99.5) (88.1 to 97.7)
p-values for pairwise comparisons between groups for Beery-Buktenica developmental tests
Assessment 1 versus 2 1 versus 3 1 versus 4 1 versus 5 2 versus 3 2 versus 4 2 versus 5 3 versus 4 3 versus 5 4 versus 5
Visual motor
integration
0.78 0.83 0.56 0.26 0.62 0.73 0.15 0.44 0.39 0.1
Visual perception 0.28 0.98 0.04* <0.001* 0.31 0.26 0.004* 0.05* <0.001* 0.13
Motor coordination 0.87 0.42 0.96 0.68 0.33 0.92 0.79 0.41 0.23 0.74
Treatment groups: ART-Def: ART deferred until symptomatic, ART-40W: early ART until 40 weeks then planned interruption, ART-96W: early
ART until 96 weeks then planned interruption. Control groups: HEU: HIV-exposed uninfected, HU: HIV-unexposed.
a1 participant and b2 participants did not complete the test. *Significant differences.
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clinical guidance, is similar to HIV-uninfected neighbourhood
controls. However, poorer visual perception in HIV-infected chil-
dren, irrespective of ARTstrategy, requires further exploration.
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